
Dec 22 (Reuters) - Shionogi & Co Ltd 4507.T:
SHIONOGI EXPANDS RARE DISEASE PRESENCE WITH PLANNED ACQUISITION OF GLOBAL RIGHTS TO TANABE PHARMA CORPORATION'S RADICAVA ORS (EDARAVONE) AND IV RADIC
TO PAY LUMP SUM OF $2.5 BILLION TO TANABE PHARMA UPON COMPLETION OF PROCEDURES
MAY PAY A ROYALTY ON FUTURE SALES, SUBJECT TO CERTAIN CONDITIONS
TRANSACTION EXPECTED TO BE IMMEDIATELY ACCRETIVE IN FY26, ADDING APPROXIMATELY USD 700 MILLION IN ANNUAL GLOBAL SALES